Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults

NCT02355210 · View on ClinicalTrials.gov ↗

Study Summary

This study evaluates the effect of a dietary supplement to improve gut health. The participants will take one of six dietary treatments for three weeks, and the gut bacteria and the gut intestinal barrier will be assessed to determine if these dietary treatments beneficially change these markers of gut health.

Interventions

  • DIETARY_SUPPLEMENT Bifidobacteria adolescentis BD1
  • DIETARY_SUPPLEMENT Bifidobacteria animalis subsp. lactis BB-12
  • DIETARY_SUPPLEMENT Bifidobacteria adolescentis BD1 and galactooligosaccharide
  • DIETARY_SUPPLEMENT Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide
  • DIETARY_SUPPLEMENT galactooligosaccharide

Study Locations (1)

Illinois

  • Rush University Medical Center — Chicago

Trial Details

FieldValue
Enrollment Target 151 participants
Start Date 2013-06
Est. Completion 2015-10
Phase NA

Sponsor

Rush University Medical Center

168 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02355210

The ClinicalTrials.gov registry entry for NCT02355210 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 168 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Intestinal Microbiota and Barrier Function appearing as the primary indexed condition, and to 5 interventions — of which Bifidobacteria adolescentis BD1 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02355210 reports 1 study location spanning 1 distinct geographic area — top geographies include Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02355210 about?

NCT02355210 is a clinical study titled "Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults". This study evaluates the effect of a dietary supplement to improve gut health. The participants will take one of six dietary treatments for three weeks, and the gut bacteria and the gut intestinal barrier will be assessed to determine if these dietary treatments beneficially change these markers of ...

What is the current status of trial NCT02355210?

This trial is currently completed. It is a NA study. The enrollment target is 151 participants. The study started on 2013-06. Estimated completion is 2015-10.

What conditions does trial NCT02355210 study?

This clinical trial studies the following conditions: Intestinal Microbiota and Barrier Function. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02355210?

The interventions under investigation include: Bifidobacteria adolescentis BD1 (DIETARY_SUPPLEMENT), Bifidobacteria animalis subsp. lactis BB-12 (DIETARY_SUPPLEMENT), Bifidobacteria adolescentis BD1 and galactooligosaccharide (DIETARY_SUPPLEMENT), Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide (DIETARY_SUPPLEMENT), galactooligosaccharide (DIETARY_SUPPLEMENT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02355210?

This trial is sponsored by Rush University Medical Center, which has 168 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02355210 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial